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Eosinophils are often predominant inflammatory leukocytes infiltrating oral squamous carcinoma (OSC) sites.
Prostaglandins are secreted by oral carcinomas and may be involved in eosinophil infiltration. The objective of this
study was to determine the factors contributing to eosinophil migration and potential anti-neoplastic effects on
OSC. Eosinophil degranulation was evaluated by measuring release of eosinophil peroxidase (EPO). Eosinophil
chemotaxis towards OSC cells was assessed using artificial basement membrane. Eosinophil infiltration was
prominent within the tissue surrounding the OSC tumor mass. We observed growth inhibition of the OSC cell line,
SCC-9, during co-culture with human eosinophils, in vitro, which correlated with EPO activity that possesses growth
inhibitory activity. The PGD2 synthase inhibitor, HQL-79, abrogated migration towards SCC-9. Our data suggest that
OSC-derived PGD2 may play an important role via CRTH2 (the PGD2 receptor on eosinophils) in eosinophil
recruitment and subsequent anti-tumor activity through the action of eosinophil cationic proteins.
Keywords: Eosinophils, Oral squamous carcinoma, Prostaglandin D2, HQL-79, TransmigrationBackground
Eosinophils are bone marrow-derived, tissue-dwelling
granulocytes found transiently in the blood circulation en
route to tissue inflammatory sites. They are prominent cells
in allergic inflammation, asthma and parasitic helminth
infections [1]. Tumor associated tissue eosinophilia (TATE)
has long been recognized as a pathological feature
associated with a number of malignant tumor types, inclu-
ding cancer of the mouth, esophagus, larynx, pharynx,
breast, lung, intestine and genitourinary tract [2]. Although
mononuclear cells, and to a lesser extent neutrophils, are
also found in oral cancers, eosinophils when present, form
the predominant inflammatory cell population [3-5]. While
there is evidence of a positive prognosis associated with
eosinophil infiltration of grade II and III tumours [6], in
well-differentiated oral cancer of grade III and IV, the pres-
ence of TATE indicates a poor prognosis [7]. Regardless,
data on the prognostic value of TATE in other cancer types
remain inconclusive [2].* Correspondence: fdavoine@ualberta.ca
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reproduction in any medium, provided the orOSC are known to express cycloxygenase-2 (COX-2)
and to generate PGE2 [8-11]. In fact, expression of
COX-2 and PGE2 was thought to be related the
proliferation and invasiveness of OSC [12-15]. PGE2
does not possess chemotactic activity for eosinophils,
but share the same precursor, PGH2, with a potent
eosinophil chemotactic molecule, PGD2 [16-18]. In this
study we hypothesized that OSC synthesize and release
PGD2 which in turn is responsible for specific chemotaxis
of eosinophils towards OSC.Methods
Paraffin embedded tissues of the corresponding sections
were sectioned at 4 microns. The sections were then
deparaffinized and hydrated in distilled water and
stained in a Weigert’s iron hematoxylin and Biebrich
scarlet solution (9:1). A differentiation step in 1% acid
alcohol was then performed on the sections until the
eosinophil granules stained bright red, followed by
rinsing in tap water. The sections were then stained in a
0.5% lithium carbonate solution until they turned blue.
A final rinsing step was performed before the final slide
mounting steps.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Approval for the study was obtained from the local Ethics
Research Board at the Faculty of Medicine and Dentistry
(University of Alberta) and all adult subjects gave their
informed consent according to the Helsinki protocol.
Blood eosinophils from atopic donors were purified as
previously described [19]. Briefly, venous blood (100 ml)
was collected in tubes with heparin. Red cells were
sedimented using Dextran 6% (Sigma-Aldrich Canada Ltd.
Oakville, Ontario, Canada). Granulocytes were separated
from mononuclear cells by centrifugation on Ficoll Paque.
Eosinophils were separated from neutrophils by CD16
immunomagnetic negative selection using a magnetic cell
sorter (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany). Purity of eosinophil preparations was
always greater than 98%, the contaminating cells being
neutrophils and/or lymphocytes.
Co-culture assay
SCC9 (American Type Culture Collection (ATCC),
Manassas, Virginia) were seeded at 5 × 104 cells/ml in 12
well plates 24h prior addition of eosinophils at a range
of eosinophil-SCC9 concentrations. Plates were cultured
until confluence of SCC9 cells was reached in control
wells. Eosinophils were then removed and adherent cells
were fixed with 4% paraformaldehyde (Sigma-Aldrich
Canada Ltd. Oakville, Ontario, Canada) for 20 minutes
and stained with crystal violet 1% (Sigma-Aldrich
Canada Ltd. Oakville, Ontario, Canada). After a PBS
wash, cells were lysed with 15% acetic acid and absor-
bance (550 nm) was measured. Absorbance was in the
linear range for 2 × 102 to 2 × 106 eosinophils/well.
Transmigration assay
The transmigration of eosinophils through the basement
membrane components was evaluated in 24-well Biocoat
Matrigel Invasion ChambersW (Becton Dickinson, Bedford,
MA) as previously described [20]. Before the assay, SCC-9
cells were allowed to grow to confluence in the lower
chambers, washed and fresh media replaced before the
addition of 0.5 × 106 eosinophils in the upper chamber.
PGD2 synthase inhibitor HQL-79 (Cayman Chemical, Ann
Arbor, MI.) (0.1-100 μM) was added to lower chambers to
block the production of PGD2. HQL-79 is an orally avail-
able selective inhibitor of hematopoietic prostaglandin
synthase specific with an IC50 of 100 uM for PGD2 but
marginally affect the production of other prostanoids
[21,22]. The percentage of transmigration was calculated by
dividing the number of cells in the lower chamber of the
Matrigel Invasion ChamberW by total number of cells in
the lower (migrated) and upper chamber (non-migrated).
The proportion of cells recovered was always >95% of the
number of added cells and viability always above 98% as
determined by annexin V/PI assay (n = 3).EPO assay
Measurement of EPO release has been previously described
[19,23]. Briefly, eosinophil suspensions (5 × 105 cells/ml
HBSS + CaCl2 1.6 mM, 0.1% gelatin) were distributed
in 96-well plate. Cells were incubated for 30 min at
37°C. Peroxidase substrate solution for the measure-
ment of EPO was prepared by adding 800 μL of 5
mM O-phenylenediamine HCl (OPD) (Sigma-Aldrich
Canada Ltd. Oakville, Ontario, Canada) to 4 ml of
1M Tris buffer (pH 8.0) and 1.25 μL of 30% hydrogen
peroxide (Sigma). Distilled water was added to a total
volume of 10 ml. The OPD solution was added to each well
of eosinophils, incubated for 2 minutes before the reaction
was stopped with the addition of 4M H2SO4 (Sigma-
Aldrich Canada Ltd. Oakville, Ontario, Canada). Each
experiment was done in triplicate and absorbance reading
at 490 nm wavelength was done for this colorimetric assay
(Softmax, 490 nm wavelength).
PGD2 dosage
Detection of PGD2 in media after transmigration was
achieved using by EAI according to manufacturer
instructions (Prostaglandin D2 EIA Kit, Cayman chemical,
Ann Arbor, MI).
Viability assay
The apoptosis/viability assay was performed using the
BD Bioscience Annexin-V-A488 detection kit according
to manufacturer instructions. Acquisition was performed
using BD FACS-CANTO flow cytometer. Viable cells
were double negatives for ToPRO-3 and Annexin-V
-A488.
Flow cytometry
Eosinophils were incubated in the presence of anti-
CRTH-2-PE (MB16, RatIgG2a, Miltenyi Biotec, Auburn,
CA) or matched isotype control antibody. Direct
staining was used to detect the presence of specific sur-
face binding with BD FACScanto flow cytometer.
Statistical methods
All results are expressed as mean ± standard error of
mean. Comparison between the groups was made using
analysis of variance (ANOVA; Statview 5.0, SAS Institute,
Cary, NC). A p-value <0.05 was considered significant.
Results
Eosinophil infiltration in oral squamous carcinoma
Paraffin embedded oral squamous carcinomas specimens
were obtained post-surgically from a cohort of 21
subjects. Evidence of eosinophil infiltration was observed
around the tumor mass. Figure 1A depicts a specimen
with massive eosinophil infiltration in connective tissue.
A 
B 
Figure 1 TATE is observed predominantly around the tumor
mass. A: Luna staining for eosinophils in surgically-resected primary
oral squamous cancer. B: higher magnification clearly shows that


































Figure 2 Eosinophil migrates through artificial basal membrane
(Matrigel) toward SCC9. CCL11 (eotaxin 0.01μm) was used as
positive control for transmigration assay. PGD2 synthase inhibitor
(HQL-79)-treated SCC9 did not induce eosinophil transmigration (n
= 9, Mean ± SEM, p < 0.05).
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tumour cellular compartment (Figure 1B).PGD2 secretion by OSC elicit eosinophil migration
To examine the capacity of OSC to elicit eosinophil
migration we used a migration system that uses an artifi-
cial cell basement membrane (Matrigel™) to separate
compartment. Eosinophils did not migrate spontan-
eously through the lower chamber in the absence of
SCC9 cells (7 ± 2%, n = 20). In comparison, the confluent
monolayer of SCC9 cells induced migration toward OSC
through matrigel (Figure 2, 32 ± 5% n = 17, p < 0.05). To
determine whether PGD2 played a role in this migration,
a PGD2 synthase inhibitor (HQL-79) was used. Before
migration, the OSC monolayer was washed with fresh
media to ensure only de novo generation of PGD2 was
affected by the HQL-79 inhibitor. A dose response effect
of HQL-79 on SCC9 induced eosinophil migration wasobserved. At a maximal concentration (100 μM) HQL-79
reduced the migration to a level similar to background
spontaneous migration (11 ± 7%, n = 9, p < 0.05). The posi-
tive control, CCL-11 (eotaxin-1), induced migration at a
level of 43 ± 6% (n = 20, p < 0.05). HQL-79 did not impair
CCL-11-induced migration or reduced eosinophil viability
as determined by flow cytometry (data not shown). The
secretion PGD2 was also confirmed by enzyme-linked im-
munosorbent assay (EIA) in SCC9 confluent wells after
transmigration, a mean concentration 1.5 ± 0.4 nM of
PGD2 was detected in the 4 experiments tested. The
addition of HQL-79 (100 μM) reduced the PGD2 concen-
tration below detection limit.
Eosinophils inhibited OSC growth
Figure 3A shows a representative confluent layer of OSC
after 5 days of culture. In contrast, adding eosinophils
prevented OSC from reaching confluence (Figure 3B). In
an attempt to potentiate eosinophil survival and function
and potentially decrease tumor growth, we added IL-2
(100 ng/ml), IL5 or a combination to the culture media.
Figure 3C depicts the mean results of 5 independent
co-culture assays. Maximum growth inhibition (60 ± 7%,
n = 5, p < 0.05) was achieved in co-culture with a 25:1 ratio
of eosinophil: SCC9. The growth of OSC was unaffected
















































Figure 3 Eosinophils inhibit the formation of monolayers of the
oral cancer cell line, SCC9. A: Representative confluent monolayer
of SCC9, 5 days after culture, Nuclei are stained with DAPI for easier
identification of SCC9 after washing out eosinophils (red bar = 100 μm).
Eosinophils were removed from wells before staining B: Co-culture
with eosinophils prevented SCC9 cell growth. (25:1 eosinophil-SCC9
ratio in media) C: Mean growth inhibition observed in 5 independent
experiments with different eosinophil-SCC9 ratio. IL-5 was used to
sustain eosinophil viability except in control group. Reference group
(0% growth inhibition) represent SCC9 incubated without addition of
cytokines or eosinophils that reached confluence (5 days). SCC9 + IL-5
and SCC9 + IL-5 + IL-2 represent control groups for the effect of
cytokines without eosinophil co-incubation. All data are represented by
Mean ± SEM * p < 0.05.
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incubated inhibition reached only 18 ± 4% (n =5, p < 0.05).
The addition of IL-5 and IL-2 increased SCC9 growth
inhibition when co-incubated with eosinophils ratio of
10:1 (25 ± 6%, n = 5) and 25:1 (39 ± 8%, n = 5, p < 0.05).
Growth inhibition of OSC was associated with eosinophil
mediator release and eosinophil cytolysis
Eosinophil peroxidase (EPO) is a potent cytotoxic
protein stored by eosinophils. We observed two forms of
EPO release: first from necrotic non-IL-5-treated
eosinophils and those stimulated by IL-2. In contrast,
negligible EPO activity was detected in the supernatant
of IL-5 treated co-culture of cells associated with the
minimum growth inhibition (Figure 4A). Eosinophils
viability in co-culture medium was measured imme-
diately after control OSC reached confluence (after 5 days).
Eosinophil viability was reduced under medium alone
conditions but remained well above 80% in medium
containing IL-5 (Figure 4B). In IL-2 + IL-5-treated groups,
eosinophil viability remained unchanged indicating that the
EPO activity measured was unlikely to be attributable to
necrosis. Since IL-5 alone did not induce significant EPO
release or OSC growth inhibition, IL-2 plus IL-5 appeared
to induce EPO release without exerting an effect on
eosinophil viability thereby contributing to OSC
growth inhibition. These results indicated that OSC
growth inhibition in untreated medium might be a result of
eosinophil necrosis, cell membrane disruption and inevit-
able toxic mediator release by cytolysis. Maximum EPO
activity correlated with maximum growth inhibition. These
results suggest that cytotoxic mediator release may be a
mechanism by which eosinophil inhibit the growth of OSC.
Discussion
Eosinophil infiltration around tumor nests is a frequent
feature of OSC and is accompanied by a mixed lymphocyte
response [6]. This infiltration often correlates with depos-





















































































P < 0.05 vs Control
Figure 4 SCC9 growth inhibition correlate with EPO release and cell viability. A: IL-2 induced release of Eosinophil peroxidase (EPO)
in culture media is associated with inhibition of oral cancer cell proliferation. EPO was measured by a colorimetric assay using the substrate
O-phenylenediamine dihydrochloride. B: Viability of eosinophils in co-culture with oral squamous cancer cells. Viability was measured using flow
cytometry by assessing cell integrity using Topro3 DNA dye and absence of apoptosis with Annexin V. All data are represented by Mean ± SEM *
p < 0.05 for eosinophil:SCC9 co-culture compared with the respective controls without cytokines.
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novo secretion of PGD2 by the OSC cell line, SCC-9, the
matrigel transmigration experiments, and inhibition with
the PGD2 synthase inhibitor, HQL-79, all combine to
suggest that PGD2 may be an important mediator in
tumor-induced recruitment of eosinophils.
Previous studies have reported PGE2 secretion by OSC
[15,25,26] but there has been no evidence that this pros-
taglandin exerts chemoattractive activity on eosinophils;
however a closely related prostaglandin, PGD2, is known
for its chemotactic activity on eosinophils [16-18]. In
this study we report that eosinophils exhibit potent
growth-inhibitory activity against the oral cancer cell
line, SCC9 which was associated with eosinophil specific
EPO release in culture medium. There is no evidence to
date that cytotoxic eosinophil granule deposition plays
a role in vivo and no data so far exist to support a
correlation between granule deposition in OSC and
favorable prognosis. In our experiments, we observed
that inhibition of OSC growth correlated with detectable
cytotoxic granule enzyme EPO activity in culture medium.
This association between OSC growth inhibition and
eosinophil mediator release was observed regardless
of eosinophil viability in the absence of factors that
sustain viability (IL-5) thus disrupting eosinophil cell
membranes resulting in a non-specific cytolytic release
of granular content.
Immunotherapy using IL-2 has been shown to have
moderate success against some tumors and is often
associated with “unexpected” but significant eosinophilia
[27], which resulted in assumptions suggesting that
eosinophils possess anti-tumor activity, at least in vitro[28]. Indeed, IL-2 is recognized as a potent regulator of
eosinophil activation, in vitro [29,30]. The effects of IL-2
include the release of cytotoxic granules, generation of
superoxide radicals [31,32] and production of autocrine
IL-2 [29,30]. IL-2-induced TATE (corollary to treatment
of renal cancer), close proximity of activated eosinophils
with bladder tumor cells and the subsequent deposition of
eosinophil cationic granules were shown to be associated
with a favourable outcome [33]. In contrast, the presence
of IL-2-induced eosinophilia was considered predictive of
the failure of therapy in renal cancer [34].
Despite the significant in vitro effects we observed with
OSC, eosinophils appeared to be mostly recruited around,
but not within OSC masses. As well, there was very little
evidence of eosinophil granule deposition ex vivo. Regard-
less, basic proteins from eosinophil granules are extremely
cytotoxic, thus, small concentration of free exocytosed
granules may be sufficient to exert a potent inflammatory/
cytotoxic response against tumor cells [35]. Recent studies
from our group suggested that cell-free granules from
eosinophils can secrete their content via direct stimulation
of functional cytokine and chemokine membrane receptors
for present on the granule membrane, in the absence of an
intact cell [36]. In addition to these potential cytotoxic
effector activities, eosinophils are also capable of exerting
an immunoregulatory role in relation to the tumor environ-
ment. Eosinophils secrete a wide range of cytokines
chemokines and growth factors [37] and these may further
contribute to the biological and immunological role of the
eosinophil in OSC.
Finally, the cyclooxygenase-2 (COX-2) inhibitor,
NS398, was reported to inhibit OSC proliferation by
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chemoattractant for eosinophils. In contrast, we show
that PGD2 is a potent chemoattractant for eosinophils,
and may contribute to eosinophilic infiltration via its
specific PGD2 receptor on eosinophil, CRTH2, which is
also a marker of TH-2 subset of helper T-cells [16].
Whether PGD2 also enhances the potential of
eosinophils to kill target cells by inducing exocytosis and
subsequent deposition of cytotoxic granule proteins
remains unknown and is the subject of a separate study.
Thus, our data suggest that eosinophils may contribute
to the inflammatory response observed in OSC and may
limit tumor progression.
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